New Therapy for Parkinson’s ‘Off’ Periods Shows Promising Results in Preclinical Studies
CVT-301, an inhalable drug under development by Acorda Therapeutics to treat Parkinson’s symptoms during “off” periods when currently available drugs don’t adequately work, showed promising results in preclinical Phase 1 and 2 studies. Since the late 1960s, levodopa has been the most common and efficient oral drug used for managing Parkinson’s motor…